(Q51430567)

5 April 2018

title

The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. (English)

1 reference

5 April 2018

0 references

1 reference

Ahlskog JE

1

1 reference

5 April 2018

Uitti RJ

2

1 reference

5 April 2018

O'Connor MK

3

1 reference

5 April 2018

Maraganore DM

4

1 reference

5 April 2018

Matsumoto JY

5

1 reference

5 April 2018

Stark KF

6

1 reference

5 April 2018

Turk MF

7

1 reference

5 April 2018

Burnett OL

8

1 reference

5 April 2018

language of work or name

English

0 references

publication date

1 November 1999

1 reference

5 April 2018

published in

Movement Disorders

1 reference

5 April 2018

volume

14

1 reference

5 April 2018

issue

6

1 reference

5 April 2018

page(s)

940-946

1 reference

5 April 2018

Neurotransmitter transporters (plus): a promising new gene family

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Pharmacological modifications of dopamine transmission do not influence the striatal in vivo binding of [3H]mazindol or [3H]cocaine in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Lack of dopamine receptor agonists effect on striatal dopamine transporter binding sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Dopamine transporter binding in rat striatum and nucleus accumbens is unaltered following chronic changes in dopamine levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat--an autoradiographic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Pharmacologic profile of ropinirole: a nonergoline dopamine agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199911%2914%3A6%3C940%3A%3AAID-MDS1005%3E3.0.CO%3B2-Y

10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018